跳至主要内容
临床试验/ISRCTN05511098
ISRCTN05511098已完成不适用

The probiotic Bifidobacterium breve strain BBG-001 administered early to preterm infants to prevent infection, necrotising enterocolitis and death: a double-blind randomised placebo-controlled trial

Queen Mary, University of London (UK)0 个研究点目标入组 1,300 人开始时间: 2009年9月24日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Both males and females, born before 31 completed weeks of gestation, i.e. up to and including 30 weeks + 6 days by the best estimate of Expected Date of Delivery (usually by first trimester antenatal ultrasound, alternatively calculated from the first day of the last menstrual period [LMP])
  • 2. Less than 48 hours old
  • 3. With written informed parental consent
  • 4. Babies already on antibiotics for suspected or proven infection are eligible for recruitment to the study

排除标准

  • 1. A lethal congenital abnormality known at trial entry
  • 2. Any known gastrointestinal malformation
  • 3. No realistic prospect of survival

研究者

发起方
Queen Mary, University of London (UK)

相似试验